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Abstract 
Methylglyoxal (MG) can cause protein glycation, resulting in cell damage and dysfunction. Accumulation of MG and 
its downstream metabolite Nε‑(carboxyethyl)lysine (CEL) has been identified in several variations of nephropathy, 
including diabetic, hypertensive, and gentamicin‑induced nephropathies. In this study, we investigated the effects of 
low‑molecular‑weight chitosan (lmw‑chitosan) on MG‑induced carbonyl stress in aristolochic acid‑induced nephropa‑
thy. We used a buffer to investigate whether MG could be scavenged by lmw‑chitosan in vitro. In addition, we also 
used a mouse model of aristolochic acid‑induced nephropathy, which exhibits 12‑fold greater accumulation of MG in 
the kidneys than that found in control animals, to examine whether lmw‑chitosan could decrease MG levels in vivo. 
Examination of the binding of lmw‑chitosan with MG in vitro demonstrated that the concentration of lmw‑chitosan 
necessary to achieve 50% inhibition was 4.60 µg mL−1. Treatment with lmw‑chitosan (500 mg kg−1 day−1 orally) for 
14 days significantly decreased renal MG accumulation from 212.86 ± 24.34 to 86.15 ± 33.79 µg g−1 protein (p < 0.05) 
and CEL levels from 4.60 ± 0.27 to 2.84 ± 0.28 µmol µg−1 protein (p < 0.05) in the aristolochic acid‑induced nephrop‑
athy model. These data suggest that lmw‑chitosan might represent a novel treatment modality for MG‑related 
diseases such as nephropathy.
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Background
Nephropathy can lead to the acquisition of end-stage 
renal disease, which is associated with major health 
problems. Causes of nephropathy include medications 
or disease, as well as the toxicity associated with com-
pounds such as the organic by-product methylglyoxal 
(MG). Aristolochic acid (AAN)- and gentamicin-induced 
nephropathies are both related to MG accumulation 
in the kidney (Li et al. 2012, 2013). The pathogenesis of 
diabetic nephropathy and its associated complications 
are primarily related to MG and its downstream metab-
olites, which cause injury to the kidneys (Rabbani and 
Thornalley 2011). Additionally, increased levels of MG 
and advanced glycation end products (AGEs) have been 
identified in the kidneys of spontaneously hyperten-
sive rats (Wang et  al. 2004). MG can also cause oxida-
tive stress. MG is generated during the process of tissue 
injury repair, which places additional energy demands 
on cells. MG, formed as a byproduct of glycolysis and 
lipid and amino acid metabolism, modifies proteins and 
interferes with protein function (Rabbani and Thornal-
ley 2012). Furthermore, Nε-(carboxyethyl)lysine (CEL), 
the downstream AGE of MG, is also known to enhance 
inflammation (Rabbani and Thornalley 2011). To date, 
only metformin has been approved as an effective MG-
reducing agent by the US Food and Drug Administration. 
However, this drug is not suggested for use in patients 
with renal insufficiency due to its toxicity. Therefore, an 
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effective and potent anti-MG agent is needed for better 
prevention and treatment of MG-induced renal injury.
Chitosan is a natural polysaccharide with a high molec-
ular weight (500–1,000  kDa) and has been widely used 
in the pharmaceutical, food, and cosmetic industries 
(Zhang et al. 2010). Upon hydrolyzation into low-molec-
ular-weight chitosan (lmw-chitosan), it becomes highly 
water-soluble and therefore has more biological applica-
tions. For example, lmw-chitosan can be utilized as an 
antibacterial agent, antifungal agent, antidiabetic drug, 
and as a lipid-lowering medication (Lee et al. 2003; Sey-
farth et al. 2008; Anraku et al. 2010; Chen et al. 2012). In 
addition, lmw-chitosan has been shown to have protec-
tive effects on the kidneys in studies on diabetes (Yoon 
et al. 2008). However, the molecular mechanisms under-
lying these effects have not been elucidated.
Lmw-chitosan can also be used as an agent for kidney-
specific targeting and drug delivery. For example, con-
jugation of lmw-chitosan nanoparticles with drugs that 
benefit the kidney such as catechol or tripterygium gly-
coside have been investigated by multiple laboratories 
(Qiao et al. 2014; Chen et al. 2013). Conversely, the dem-
onstration that the levels of MG are increased 12-fold in 
the kidneys of AAN mice suggests that this might rep-
resent a good model for investigating the effect of lmw-
chitosan on decreasing physiological MG accumulation 
in vivo.
While MG and CEL are important in disease pathogen-
esis, the relationships between lmw-chitosan and MG or 
CEL have not been determined. Therefore, in this study 
we aimed to elucidate the effects and underlying mech-
anisms of lmw-chitosan on MG and CEL accumulation 
in vitro and in vivo.
Results
Inhibitory activity of lmw‑chitosan in vitro and in vivo
The data of MG chelation and inhibition by lmw-chi-
tosan in vitro are shown in Figure 1a. The concentration 
of lmw-chitosan required for 50% inhibition was deter-
mined to be 4.60 µg mL−1. MG levels in the in vivo study 
were ascertained by HPLC and then normalized with 
protein assay. MG levels in the kidneys of Group A mice 
were significantly higher than those in Group C mice 
(212.86 ± 24.34 vs. 18.23 ± 8.05 μg g−1 protein, respec-
tively, p < 0.05). Treatment with lmw-chitosan decreased 
MG levels to 86.15  ±  33.79  μg  g−1 protein (p  <  0.05 
vs. Group AM; Figure  1b). Additionally, the lmw-chi-
tosan only group (Group M) exhibited an MG level of 
6.26 ± 1.79 μg g−1 protein.
Immunohistological staining and quantitative detection 
of CEL
Immunochemistry was performed to visualize CEL 
expression in the kidneys (Figure 2A). We observed that 
CEL staining was present in several monocytes of the 
desquamation tubule region and that lmw-chitosan treat-
ment significantly decreased the level of CEL staining 
(p < 0.05).
The quantitative data of CEL expression in mouse kid-
neys are shown in Figure 2B. The levels of CEL in Group 
A mice were significantly higher than those in Group 
C mice (4.6  ±  0.27 vs. 2.24  ±  0.08  μmol  µg−1 protein, 
respectively). After lmw-chitosan treatment, the CEL lev-
els in Group AM mice decreased to 2.84 ±  0.28 μmol/
µg protein (p  <  0.05 vs. Group A). Additionally, the 
lmw-chitosan only group (Group M) had a CEL level of 
1.86 ± 0.12 μmol µg−1 protein.
Figure 1 Inhibitory effects of lmw‑chitosan on MG in vitro and in vivo. a Lmw‑chitosan binds to MG and decreases the level of MG in vitro. The 
inhibition curve of lmw‑chitosan on MG binding is shown. The concentration necessary to achieve 50% inhibition was 4.60 µg mL−1, n = 3. b Group 
C represents the control group. Group A was induced by AA (10 mg kg−1 day−1) for 5 days. Group AM represents lmw‑chitosan‑treated AAN mice. 
Group M represents normal mice treated with lmw‑chitosan. MG levels were observed to increase in AAN mice; however, this increase is reversed in 
lmw‑chitosan‑treated AAN mice. *p < 0.05, compared to Group C; #p < 0.05, compared to Group A, n = 5–6.
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Effects of lmw‑chitosan on glutathione levels in the 
kidneys of AAN mice
Glutathione is an important anti-oxidant, and the relative 
level of glutathione in a cell, compared to the level of its 
oxidized form, serves as an indicator of oxidative stress. 
In addition, glutathione is a required cofactor during MG 
detoxification. We determined that the intrarenal glu-
tathione levels in Group A mice were lower than those in 
Group C mice (0.78 ± 0.15 vs. 2.46 ± 0.41 μg g−1 protein, 
respectively; p  <  0.05; Figure  3); however, glutathione 
levels did not recover significantly after administration of 
lmw-chitosan treatment (Group AM: 1.31 ± 0.46 μg g−1 
protein, p > 0.05 vs. Group A). Additionally, the lmw-chi-
tosan only group (Group M) demonstrated a glutathione 
level of 2.73 ± 0.40 μg g−1 protein.
Hypothetical scheme of the role of lmw‑chitosan in disease 
prevention
Figure 4 illustrates a mechanism by which MG accumula-
tion leads to disease and serves as a target for lmw-chitosan 
binding. Initially, elevated levels of MG and CEL cause 
significant carbonyl stress in AA-injected mice and in dis-
eases such as nephropathy, and subsequent administra-
tion of lmw-chitosan can successfully reverse the increase 
in MG and CEL levels. However, the lack of response in 
our animal model suggests that the glutathione level does 
not represent the primary target of lmw-chitosan; instead, 
we suggest that the reversal of MG and MG-derived CEL 
build-up by lmw-chitosan is the key mechanism of this 
treatment against nephropathy.
Discussion
In this study, we investigated the effects of lmw-chitosan 
on carbonyl stress in mice with AAN. We found that 
AAN mice treated with lmw-chitosan showed improved 
renal function, and that lmw-chitosan treatment signifi-
cantly decreased renal MG accumulation and CEL levels. 
Thus, our data demonstrated that lmw-chitosan could 
decrease renal damage in AAN by ameliorating the accu-
mulation of MG and CEL in the kidney.
Furthermore, in a previous study, a clinical trial 
was conducted to characterize the effects of chitosan 
Figure 2 Effects of lmw‑chitosan on CEL concentrations in renal 
tissues of mice. A Immunostaining of CEL in the mouse kidney. a 
Control group (Group C); b mice induced by AA (10 mg kg−1 day−1) 
for 5 days (Group A); c lmw‑chitosan‑treated AAN mice (Group AM); 
and d normal mice treated with lmw‑chitosan (Group M). CEL staining 
can be observed in the tubular region of monocytes (arrow). Nuclei 
were counterstained with hematoxylin. Original magnification: 
×400 . B ELISA of CEL levels in mouse kidneys. Group C represents 
the control group. Group A was induced by AA (10 mg kg−1 day−1) 
for 5 days. Group AM represents lmw‑chitosan‑treated AAN mice. 
Group M consisted of normal mice treated with lmw‑chitosan. It can 
be observed that CEL was increased by threefold in Group A, and that 
this effect was reversed in Group AM. *p < 0.05, compared to Group C; 
#p < 0.05, compared to the Group A, n = 5–6.
Figure 3 Effects of lmw‑chitosan on glutathione concentrations in 
mouse kidney. Group C represents the control group. Group A was 
induced by AA (10 mg kg−1 day−1) for 5 days. Group AM represents 
lmw‑chitosan‑treated AAN mice. Group M consists of normal mice 
treated with lmw‑chitosan. Glutathione levels decreased in the 
kidneys of AAN mice; treatment with lmw‑chitosan did not signifi‑
cantly reverse this effect. *p < 0.05, compared to Group C; #p < 0.05, 
compared to the Group A, n = 5–6.
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administration in patients with renal failure that were 
undergoing long-term stable hemodialysis treatment. 
The data revealed that patients receiving chitosan 
(4,050  mg  day−1) for 4  weeks had significantly lower 
blood urea nitrogen and serum creatinine levels than 
those in patients not receiving chitosan (Jing et al. 1997). 
Similarly, we found that lmw-chitosan ameliorated clini-
cal chemistry parameters and improved histology in our 
mouse model (Additional files 1, 2: Figures S1, S2).
MG can glycate proteins at a significantly higher level 
than can glucose (Thornalley 2005); in addition, MG-
mediated protein modification can alter the biological 
activity of the glycated protein and produce toxic AGEs. 
Oxidative stress induced by MG can also cause cell dam-
age. Thus, MG has a higher impact than blood glucose on 
diabetic neuralgia, and regulating MG levels is an impor-
tant preventative measure against the development of 
diabetic complications (Bierhaus et al. 2012).
Several pharmacological interventions for prevent-
ing MG-related injuries have been proposed, and sev-
eral chemical agents, including thiamine (Rabbani et  al. 
2009) and aminoguanidine (Thornalley 2003), have been 
tested. However, most of these agents cannot be used 
for treatment because of their toxicity, instability, or low 
potency. Among all the available agents, only metformin 
is widely used for the treatment of diabetes and for low-
ering blood sugar. However, metformin is not suggested 
for use in patients with renal function insufficiency 
because of the risk of lactic acidosis, a life-threatening 
side effect of metformin that occurs only in 8 out of every 
1,00,000 patients but has a mortality rate of up to 50%. 
Despite this drawback of metformin, because no effec-
tive MG inhibitors are currently available, doctors still 
use metformin to treat MG-related nephropathy. There-
fore, the development of a novel, safe, and effective MG 
inhibitor is urgently needed. In contrast, lmw-chitosan 
has been used widely in the pharmaceutical industry 
and was introduced in humans as a lipid-lowering agent 
(Choi et al. 2012); there have been no adverse effects of 
chitosan reported to date. Therefore, we propose that 
lmw-chitosan might be an ideal supplementary strategy 
for preventing MG-related complications in humans.
In addition to its impact on diabetes, MG was recently 
found to be related to the pathogenesis of numerous 
other diseases. Ahmed et al. (2014) showed that MG and 
MG-derived AGEs might be increased in arthritis. Addi-
tionally, Tikellis et  al. (2014) increased the plasma MG 
levels of mice to the levels observed in diabetic mice by 
addition of 1% MG to the drinking water and by inhib-
iting its primary clearance enzyme, glyoxalase I. Eugly-
cemic mice with increased MG levels showed increased 
vascular adhesion, inflammation, and augmented athero-
genesis, and the pathophysiology was similar to that 
observed in hyperglycemic mice with diabetes. Therefore, 
Figure 4 The protective mechanism of lmw‑chitosan. Lmw‑chitosan can block MG and CEL accumulation and might improve the damage result‑
ing from protein dysfunction and inflammation. Interactions with carbonyl and oxidative stressors could promote an increase in overall stress. 
However, the role of lmw‑chitosan on carbonyl stress is more vital than that on oxidative stress.
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it was suggested that MG plays an important role in the 
development of inflammation- and physiology-related 
diseases.
In our present study, we show that MG can be che-
lated by lmw-chitosan in  vitro, and demonstrate that 
lmw-chitosan can also lower the MG levels in renal tis-
sue in  vivo in an animal model, which might prevent 
renal injury by AA. Limitations of our study include that 
the question of whether MG is enzymatically metabo-
lized by lmw-chitosan or binds to lmw-chitosan remains 
unanswered, and that the effects and toxicities of the 
end products from MG and lmw-chitosan association 
are also not clear. Further study is needed to address 
these issues.
Conclusions
In conclusion, our finding that lmw-chitosan could 
decrease the accumulation of MG and CEL might be val-
uable for understanding the mechanisms underlying the 
bioactivities of chitosan. Furthermore, our data demon-
strated that lmw-chitosan might be useful for the treat-
ment of severe renal diseases, although further evidence 
is needed to confirm this.
Methods
Chemicals
Crab shell chitosan (84% deacetylated; approximately 
1,100 kDa) was obtained from Ohka Enterprises Co. Ltd. 
(Kaohsiung, Taiwan). A CEL detection kit was obtained 
from Cell Biolabs Inc. (San Diego, CA, USA). A glu-
tathione assay kit was obtained from Cayman Chemical 
Co. (Ann Arbor, MI, USA). Anti-CEL antibodies were 
purchased from Cosmo Bio Co. (Tokyo, Japan). A poly-
mer detection system, which includes blocking reagent 
A and B, was purchased from Nichirei Biosciences Inc. 
(Tokyo, Japan).
Preparation of chitosanase and lmw‑chitosan
Chitosan was used to induce bamboo chitosanase, which 
was in turn utilized to digest chitosan (1,100  kDa) into 
lmw-chitosan (~29 kDa), as previously described (Chang 
et al. 2011). Briefly, bamboo (Bambusa oldhamii) shoots 
were coated with chitosan and stored at 25°C to induce 
chitosanase, which was isolated, and its activity was 
measured. Chitosan was suspended in 4.5% acetic acid, 
digested with 180  U chitosanase at 50°C for 18  h, and 
purified before use.
Determination of the inhibitory effects of lmw‑chitosan 
on MG in vitro and in kidney samples
MG levels were determined using HPLC. Lmw-chitosan 
was diluted to different concentrations (1, 2, 5, 10, and 
40 µg mL−1) for testing the MG inhibition effect in vitro. 
In addition, kidney homogenates were diluted fourfold, 
and 20  μL diluted homogenate was used to detect the 
MG level. To each sample, 2  μL ammonium chloride 
buffer (pH 10) was added to create an alkaline environ-
ment for the derivatization reaction. The derivative 
reagent, 50  µL 7.5  ×  10−4  M DDP, was added to each 
sample, and the reaction mixture was incubated at 60°C 
for 30 min in the dark. The reaction was then stopped by 
addition of 500 µL 0.01 M citric acid buffer (pH 6). The 
mixture was vortexed, spun down, incubated on ice for 
10  min, and then centrifuged at 12,000  rpm for 10  min 
at 4°C. The supernatant was filtered with a 0.45 µm filter 
to remove impurities and then layered onto an ODS col-
umn for separation at 33°C (Biosil, 250 mm × 4.6 mm ID; 
5 μm particle size; Biosil Chemical Co. Ltd., Taipei, Tai-
wan). Acetonitrile was used as the mobile phase: 0.01 M 
citric acid buffer  =  3:97, v/v; flow rate  =  0.7  mL/min, 
Ex/Em = 330/500 nm. All samples were analyzed within 
24 h.
Animal treatment and sample preparation
A total of 23 six-week-old female C3H/He mice were 
purchased from the National Laboratory Animal 
Breeding and Research Center (Taipei, Taiwan). The 
mice were divided into three groups of six mice each 
plus a control group consisting of five animals after 
1 week of acclimation. The control (Group C) and lmw-
chitosan only (Group M) groups were injected with 
0.1  mL normal saline each day for 5  days (days 1–5, 
IP), whereas the disease (Group A) and therapy (Group 
AM) groups were injected with 0.1 mL 10 mg kg−1 AA 
(IP) each day for 5 days. The mice in Groups AM and 
M then received lmw-chitosan (500 mg kg−1 day−1, PO) 
for 14  days after AA injection, while mice in Groups 
C and A received the same volume of water. The mice 
were anesthetized with isoflurane and sacrificed by 
drawing blood from the inferior vena cava. The kidneys 
were then harvested and immediately put on ice. The 
kidneys were homogenized with a motorized homog-
enizer unit at 6,000  rpm by using phosphate buffered 
saline (PBS); the resulting homogenates were stored at 
−80°C until use.
Determination of CEL concentrations in kidney samples
The CEL concentrations were determined using a com-
mercial kit. Briefly, all kidney homogenate samples 
were diluted in PBS to a final total protein content of 
10 μg mL−1. One hundred microliters of each sample or 
standard was then added to a protein adsorbent plate, 
which was incubated overnight at 4°C. After incubation, 
the plate was washed with PBS twice and subsequently 
incubated with 200 µL Assay Diluent buffer for 1.5 h. The 
plate was then washed three times with 250 μL wash buffer 
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and incubated with anti-CEL antibodies at room tempera-
ture for 1 h on an orbital shaker. Then the plate was again 
washed with wash buffer three times and incubated with 
secondary horseradish peroxidase-conjugated antibodies 
for 1.5 h at room temperature on an orbital shaker. Next, 
the plate was washed with wash buffer five times and then 
incubated with 100  μL Substrate Solution at room tem-
perature for 15 min on an orbital shaker. The enzyme reac-
tion was stopped by adding 100 μL Stop Solution to each 
well. The absorbances of the reaction mixtures were read 
immediately on a microplate reader at 450  nm. Reduced 
bovine serum albumin was used as an assay blank.
Immunochemical staining of CEL
To determine the localization of CEL by immunohis-
tochemistry, mouse kidneys were fixed with 4% para-
formaldehyde for 2  days, dehydrated with different 
concentrations of ethanol and xylene, embedded in par-
affin, and sectioned to 5  μm thickness. After blocking 
endogenous peroxidase activity by treating the sections 
with 3% H2O2 for 10 min, slides were washed three times 
with PBS. The slides were then incubated with block-
ing reagent A for 60  min at room temperature. Anti-
CEL antibodies were diluted 50-fold and incubated with 
the samples overnight, followed by washing with PBS. 
Next, the samples were incubated with blocking reagent 
B for 10  min at room temperature. The samples were 
then incubated with a secondary antibody for 10  min 
at room temperature. Subsequently, the tissue sections 
were washed for a final three times and then dried care-
fully. Two drops of the chromogen/substrate reagent was 
added to each section, and the samples were incubated in 
the dark at room temperature for 10 min. Sections were 
then counterstained with hematoxylin. Staining without 
inclusion of the primary antibody was performed as the 
negative control.
Determination of glutathione concentrations in kidney 
samples
The glutathione levels in the kidney samples were meas-
ured using a glutathione assay kit (Cayman), as previously 
described (Li et al. 2012). Briefly, the tissue homogenates 
were added to a cocktail buffer containing glutathione 
reductase, glucose-6-phosphate dehydrogenase, and 
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB). The mixture 
was incubated at 37°C in the dark, and the absorbance 
was measured at 405 nm at 5-min intervals over 30 min.
Statistical analysis
All data were expressed as means ±  standard errors of 
the means (SEMs, where n  ≤  5). The differences were 
analyzed using one-way analysis of variance (ANOVA), 
and the levels of significance among various treatments 
were determined using Scheffe’s multiple range test. Dif-
ferences with p values < 0.05 were considered statistically 
significant.
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Additional files
 Additional file 1: Figure S1. Renal function changes following 
treatment with lmw‑chitosan. Renal function is shown. The white bar 
represents CCr levels (mL min−1 kg−1), and the gray bar represents BUN 
levels (mg dL−1) after treatment with lmw‑chitosan. Group C represents 
the control group. Group A was induced by AA (10 mg kg−1 day−1) for 
5 days. Group AM represents lmw‑chitosan‑treated AAN mice. Group M 
represents normal mice treated with lmw‑chitosan.
Additional file 2: Figure S2. Renal histological changes following 
treatment with lmw‑chitosan. Sections from rat kidneys stained with 
hematoxylin and eosin were imaged by light microscopy. (A) Histology of 
kidney tissues in the control group. (B) A large number of necrotic tubules 
and desquamation after treatment with 10 mg kg−1 day−1 AA for 5 days. 
(C) Treatment of AAN mice with 500 mg kg−1 day−1 lmw‑chitosan for 14 
days resulted in a significant improvement in histology. (D) The adminis‑
tration of 500 mg kg−1 day−1 lmw‑chitosan for 14 days.
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